Investigating how blocking a specific receptor may reduce blood vessel issues in Alzheimer's disease.
Cerebrovascular involvement in Alzheimer's Disease: PAR4 Antagonism
This study is looking at how certain changes in blood vessels in the brain might affect Alzheimer's disease and aims to find a way to improve blood flow and reduce inflammation, which could help people with Alzheimer's feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11085140 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of cerebrovascular mechanisms in Alzheimer's disease (AD) and how they contribute to dementia. It specifically examines the effects of pathologic fibrin deposition in the brain's blood vessels and how this process is influenced by a receptor called PAR4. By antagonizing PAR4, the research aims to reduce thrombin generation and fibrin deposition, potentially improving blood flow and reducing inflammation in the brain. Patients may benefit from this approach if it leads to new treatments that address both AD and related cerebrovascular issues.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 65 and older who are experiencing symptoms of Alzheimer's disease or related cognitive decline.
Not a fit: Patients who are younger than 65 or those without any signs of cognitive impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve cognitive function and quality of life for patients with Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cerebrovascular disease, suggesting potential for success in this novel approach.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Hamm, Heidi E — Vanderbilt University
- Study coordinator: Hamm, Heidi E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.